SciClone Pharmaceuticals said it plans to develop and register its oral mucositis treatment SGX942 for Greater China. The drug is being developed by Soligenix after the two companies entered into a development pact in 2013.
Eli Lilly has joined Halozyme's stable of Big Pharma collaborators, recruiting the company for its drug delivery expertise in a deal worth up to $825 million.
Bayer is making a $335 million wager on the future of gene editing. The pharma company has committed $300 million in research support to a new joint venture with CRISPR Therapeutics that will operate out of Cambridge, MA. And the biotech upstart is grabbing a $35 million equity investment from Bayer, which also signaled a big appetite for more life science deals.
Building on a relationship struck last fall, Bavarian Nordic and Johnson & Johnson's Janssen unit inked a deal on Friday potentially worth $171 million plus milestones aimed at the development of a therapeutic HPV vaccine.
AstraZeneca's research arm MedImmune said it will spend $50 million to expand production in China, and will also expand its manufacturing partnership with WuXi AppTec.
Swedish contract drugmaker Recipharm is on board to help local biotech LIDDS advance its cancer therapy, agreeing to produce the drug and taking an equity stake in its partner.
Physical therapy both before and after joint replacement surgery can make the procedure--which is increasingly common in wealthy countries as populations age and grow heavier--go more smoothly and reduce associated costs. A pair of startups, patient care company Wellbe and physical therapy automation startup Kiio, have come up with a remote, monitoring system that combines software and a hand-held device to offer a range of more than 1,500 templates for physical therapy exercises.
Less than three months after AbbVie turned its back on Galapagos and a $1.4 billion deal for the late-stage autoimmune drug filgotinib, Gilead Sciences has stepped in with $725 million in cash and up to $1.35 billion in milestones to take its place in the partnership.
Takeda Pharmaceuticals and other Japanese drugmakers are latching on to regenerative medicine and stem cell research as a future growth market and quickly developing partnerships and acquiring overseas ventures to tap the market.
Biogen is bringing the Polaris Partners-backed Arsia Therapeutics into its stable of partners, signing a deal worth up to $100 million to research new ways of formulating hemophilia treatments.